Analysts take a look at ImmunoGen, Inc. (NASDAQ:IMGN) having this to say.

October 2, 2018 - By Linda Rogers

ImmunoGen, Inc. (NASDAQ:IMGN) LogoInvestors sentiment increased to 1.21 in 2018 Q2. Its up 0.26, from 0.95 in 2018Q1. It is positive, as 23 investors sold ImmunoGen, Inc. shares while 45 reduced holdings. 23 funds opened positions while 59 raised stakes. 121.66 million shares or 18.59% more from 102.59 million shares in 2018Q1 were reported.
Pinnacle holds 0.22% of its portfolio in ImmunoGen, Inc. (NASDAQ:IMGN) for 1.10M shares. Alps Advisors Inc has 0.01% invested in ImmunoGen, Inc. (NASDAQ:IMGN). Cwm Lc has invested 0% in ImmunoGen, Inc. (NASDAQ:IMGN). Us Bankshares De has 0% invested in ImmunoGen, Inc. (NASDAQ:IMGN). Assetmark holds 169 shares. Redmile Group has 12.32M shares. 1,100 were accumulated by Architects Inc. Metropolitan Life Ins New York stated it has 0% in ImmunoGen, Inc. (NASDAQ:IMGN). California Public Employees Retirement System reported 146,302 shares stake. Fifth Third Bancshares invested in 18,581 shares. Millennium Ltd Liability Corp holds 0% or 257,204 shares. Meeder Asset reported 0% in ImmunoGen, Inc. (NASDAQ:IMGN). Huntington National Bank stated it has 206 shares. Northwestern Mutual Wealth Co owns 0% invested in ImmunoGen, Inc. (NASDAQ:IMGN) for 2,000 shares. Natl Bank Of America Corp De holds 1.21M shares.

Since June 6, 2018, it had 0 insider buys, and 2 selling transactions for $165,550 activity. The insider Berkenblit Anna sold $55,350.

ImmunoGen, Inc. (NASDAQ:IMGN) Ratings Coverage

Among 2 analysts covering ImmunoGen (NASDAQ:IMGN), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. ImmunoGen had 2 analyst reports since April 6, 2018 according to SRatingsIntel. The rating was maintained by Leerink Swann with “Buy” on Friday, April 27. The firm has “Hold” rating given on Friday, April 6 by Cantor Fitzgerald. Below is a list of ImmunoGen, Inc. (NASDAQ:IMGN) latest ratings and price target changes.

27/04/2018 Broker: Leerink Swann Rating: Buy Maintain
06/04/2018 Broker: Cantor Fitzgerald Rating: Hold New Target: $5.0000 Maintain

The stock decreased 2.11% or $0.2 during the last trading session, reaching $9.27. About 1.07M shares traded. ImmunoGen, Inc. (NASDAQ:IMGN) has risen 38.52% since October 2, 2017 and is uptrending. It has outperformed by 22.90% the S&P500.

ImmunoGen, Inc., a clinical-stage biotechnology company, develops targeted anticancer therapeutics. The company has market cap of $1.38 billion. The firm develops its products using its antibody-drug conjugate technology. It currently has negative earnings. The companyÂ’s product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha for the treatment of platinum-resistant ovarian cancer; IMGN529, an ADC that is in Phase 1b/2 clinical trials for B-cell malignancies; coltuximab ravtansine, which is in Phase 2 trials for B-cell malignancies; IMGN779 that is in Phase 1 clinical trials for the treatment of acute myeloid leukemia (AML); and IMGN632, a preclinical CD123-targeting ADC for the treatment of hematological malignancies, including AML.

ImmunoGen, Inc. (NASDAQ:IMGN) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>